Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | FECH | P22830 | 1/20 | 0.45 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24167962 | 0.86 | HSPB1 (0.48) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29834731 | 0.86 | PDE7A (0.52) | ALDH1A1KDM4EMEN1LMNAGAA | |
| SCHEMBL24569945 | 0.86 | PDE7A (0.52) | ALDH1A1KDM4EMEN1LMNAGAA | |
| SCHEMBL24996637 | 0.84 | ALDH1A1 (0.40) | ALDH1A1KDM4EMEN1LMNAGLA | |
| SCHEMBL24168224 | 0.83 | ERBB2 (0.38) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL27440792 | 0.83 | CYP1A2 (0.43) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL23817308 | 0.83 | POLB (0.39) | ALDH1A1KDM4EMEN1LMNAGLA | |
| SCHEMBL26005853 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1LMNAMAPT | |
| SCHEMBL31635748 | 0.83 | ERBB2 (0.68) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL22076890 | 0.83 | ERBB2 (0.68) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903615-A | Preparation method of tocartinib and intermediate thereof | 江苏丽源医药有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-122103130-A | Tucartinib middle Process for the preparation of intermediates | — | 2026-05-29 | — | — | CN | disclosed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025202889-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9693989-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-8648087-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2090575-B1 | Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives | ARRAY BIOPHARMA INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-1971601-B1 | N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-2090575-A1 | Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives | Array Biopharma, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1971601-A2 | N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Array Biopharma Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007059257-A2 | N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | ERBB2 2/4885EGFR 4/4885NQO2 297/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | ERBB2 2/4885EGFR 4/4885NQO2 297/4885 |
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | ERBB2 691/4885EGFR 677/4885NQO2 16/4885 |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | ERBB2 2/4885EGFR 4/4885NQO2 297/4885 |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | ERBB2 2/4885EGFR 4/4885NQO2 297/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885NQO2 680/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | ERBB2 428/4885EGFR 324/4885NQO2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.